Earnings Feed
Start Free
Home/Filings/4/0000899243-18-010684
4//SEC Filing

Versant Venture Capital V (Canada), LP 4

Accession 0000899243-18-010684

CIK 0001674416other
View on SEC.govCompany Profile

Filed

Apr 23, 8:00 PM ET

Accepted

Apr 24, 7:44 PM ET

Size

30.9 KB

Accession

0000899243-18-010684

Insider Transaction Report

Form 4
Period: 2018-04-20
CRISPR Therapeutics AGCRSP
Versant Ventures IV, LLC
10% Owner
Transactions
  • Other

    Common Shares

    2018-04-20−497,053→ 2,238,979 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20+92,918→ 92,918 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−92,918→ 0 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−6,821$345,552→ 117,173 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−89,628$4,540,554→ 1,539,576 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−2,947→ 13,277 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,915$148,665→ 50,072 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,630$134,130→ 45,171 total(indirect: See footnote)
Versant Venture Capital V, L.P.
10% Owner
Transactions
  • Other

    Common Shares

    2018-04-20−497,053→ 2,238,979 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20+92,918→ 92,918 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−89,628$4,540,554→ 1,539,576 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,915$148,665→ 50,072 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−2,947→ 13,277 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−92,918→ 0 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,630$134,130→ 45,171 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−6,821$345,552→ 117,173 total(indirect: See footnote)
Versant Affiliates Fund V, L.P.
10% Owner
Transactions
  • Other

    Common Shares

    2018-04-20−497,053→ 2,238,979 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−2,947→ 13,277 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20+92,918→ 92,918 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,915$148,665→ 50,072 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−89,628$4,540,554→ 1,539,576 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−92,918→ 0 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,630$134,130→ 45,171 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−6,821$345,552→ 117,173 total(indirect: See footnote)
Versant Ophthalmic Affiliates I, L.P.
10% Owner
Transactions
  • Other

    Common Shares

    2018-04-20−497,053→ 2,238,979 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−89,628$4,540,554→ 1,539,576 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,630$134,130→ 45,171 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−2,947→ 13,277 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20+92,918→ 92,918 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−92,918→ 0 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,915$148,665→ 50,072 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−6,821$345,552→ 117,173 total(indirect: See footnote)
Versant Venture Capital V (Canada), LP
10% Owner
Transactions
  • Other

    Common Shares

    2018-04-20−2,947→ 13,277 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−89,628$4,540,554→ 1,539,576 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,630$134,130→ 45,171 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,915$148,665→ 50,072 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20+92,918→ 92,918 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−92,918→ 0 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−6,821$345,552→ 117,173 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−497,053→ 2,238,979 total(indirect: See footnote)
Versant Venture Capital IV, L.P.
10% Owner
Transactions
  • Other

    Common Shares

    2018-04-20−2,947→ 13,277 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−92,918→ 0 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−6,821$345,552→ 117,173 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−497,053→ 2,238,979 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−89,628$4,540,554→ 1,539,576 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20+92,918→ 92,918 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,630$134,130→ 45,171 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,915$148,665→ 50,072 total(indirect: See footnote)
Versant Side Fund IV, L.P.
10% Owner
Transactions
  • Other

    Common Shares

    2018-04-20−497,053→ 2,238,979 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−89,628$4,540,554→ 1,539,576 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,915$148,665→ 50,072 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−2,947→ 13,277 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20+92,918→ 92,918 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$51.00/sh−2,630$134,130→ 45,171 total(indirect: See footnote)
  • Sale

    Common Shares

    2018-04-23$50.66/sh−6,821$345,552→ 117,173 total(indirect: See footnote)
  • Other

    Common Shares

    2018-04-20−92,918→ 0 total(indirect: See footnote)
Footnotes (16)
  • [F1]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners.
  • [F10]These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.
  • [F11]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V").
  • [F12]These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.
  • [F13]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA").
  • [F14]These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.
  • [F15]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN").
  • [F16]These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, VV V CAN GP and VV V CAN each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.
  • [F2]These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein.
  • [F3]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners.
  • [F4]These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein.
  • [F5]Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV.
  • [F6]The shares are held by VV IV.
  • [F7]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members.
  • [F8]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V").
  • [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $54.00 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Documents

1 file

Issuer

CRISPR Therapeutics AG

CIK 0001674416

→
Entity typeother
IncorporatedOntario, Canada

Related Parties

1
  • filerCIK 0001612235

Filing Metadata

Form type
4
Filed
Apr 23, 8:00 PM ET
Accepted
Apr 24, 7:44 PM ET
Size
30.9 KB
View on SEC.gov